{ "ok": true, "cik": "1659617", "ticker": "MBRX", "name": "Moleculin Biotech, Inc.", "filings": [ { "form": "8-K", "filed": "2026-09-28", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926031280/0001437749-26-031280-index.htm" }, { "form": "8-K", "filed": "2026-09-25", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926031199/0001437749-26-031199-index.htm" }, { "form": "8-K", "filed": "2026-09-23", "items": [ "7.01 Regulation FD Disclosure", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005/0001437749-26-031005-index.htm" }, { "form": "8-K", "filed": "2026-09-18", "items": [ "3.01 Notice of Delisting or Failure to Satisfy a Listing Rule" ], "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/0001437749-26-030757-index.htm" }, { "form": "8-K", "filed": "2026-09-14", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926030315/0001437749-26-030315-index.htm" }, { "form": "8-K", "filed": "2026-08-31", "items": [ "7.01 Regulation FD Disclosure", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926029336/0001437749-26-029336-index.htm" } ], "events12m": 48, "healthWatch": { "window": "last 12 months", "since": "2025-09-28", "signals": [ { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 2, "latest": { "filed": "2026-09-18", "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/0001437749-26-030757-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001659617.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1659617" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up Moleculin Biotech, Inc. ($MBRX). Last filing: 8-K (7.01 Regulation FD Disclosure), 2026-09-28. 48 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 0, "revenueGrowth1y": null, "revenueGrowthPerYear": null, "yearsOfData": 5, "operatingMargin": null, "operatingMarginPrior": null, "netMargin": null, "operatingCashFlow": -22735000, "capitalSpending": 0, "freeCashFlow": -22735000, "researchAndDevelopment": 15891000, "researchShareOfRevenue": null, "cash": 8878000, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 0 }, { "fiscalYearEnd": "2022-12-31", "revenue": 0 }, { "fiscalYearEnd": "2023-12-31", "revenue": 0 }, { "fiscalYearEnd": "2024-12-31", "revenue": 0 }, { "fiscalYearEnd": "2025-12-31", "revenue": 0 } ], "totalEquity": 15006000, "totalAssets": 22126000, "equityRatio": 0.6782066347283738, "returnOnEquity": -2.2364387578302014, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": -28.42, "sharesOutstanding": 1184569, "bookValuePerShare": 12.667898619666731, "revenuePerShare": 0, "range80": null, "ifPaceHeld": null }, "edgarette": "🔖 Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity 67.8% of assets, return on equity -223.6%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Moleculin Biotech, Inc. (MBRX) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 67.8% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Moleculin Biotech, Inc. against its own record and its peers
Equity of assetsPeer median 40.3%67.8%Return on equityPeer median -1.1%-223.6%Gold tick: the median of 100–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Moleculin Biotech, Inc. (MBRX) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 67.8% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 0, "totalDebt": null, "cash": 8878000 }, "experience": { "revenueGrowth1y": null, "revenueGrowthPerYear": null, "operatingMargin": null, "operatingMarginPrior": null, "netMargin": null, "freeCashFlow": -22735000 }, "soundness": { "equityRatio": 0.6782066347283738, "returnOnEquity": -2.2364387578302014, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-09-28", "signals": [ { "code": "3.01", "label": "Exchange listing notice or transfer", "count": 2, "latest": { "filed": "2026-09-18", "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926030757/0001437749-26-030757-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": null, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001659617.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1659617" }, "speedCash": null, "harbor": { "signs": [], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 0, "name": "New ship", "plain": "no warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": -22735000, "investing": 0, "financing": 27284000, "capitalSpending": 0, "free": -22735000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": -18951000, "free": -18970000 }, { "fiscalYearEnd": "2022-12-31", "operating": -27639000, "free": -27706000 }, { "fiscalYearEnd": "2023-12-31", "operating": -23591000, "free": -23715000 }, { "fiscalYearEnd": "2024-12-31", "operating": -23862000, "free": -23875000 }, { "fiscalYearEnd": "2025-12-31", "operating": -22735000, "free": -22735000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 8878000, "shortTerm": null, "longTerm": null, "equityHoldings": null, "totalAssets": 22126000, "ladder": null, "currentRatio": 1.41, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": null, "harbor": { "signs": [], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 0, "name": "New ship", "plain": "no warning signs" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": -22735000, "investing": 0, "financing": 27284000, "capitalSpending": 0, "free": -22735000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": -18951000, "free": -18970000 }, { "fiscalYearEnd": "2022-12-31", "operating": -27639000, "free": -27706000 }, { "fiscalYearEnd": "2023-12-31", "operating": -23591000, "free": -23715000 }, { "fiscalYearEnd": "2024-12-31", "operating": -23862000, "free": -23875000 }, { "fiscalYearEnd": "2025-12-31", "operating": -22735000, "free": -22735000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 8878000, "shortTerm": null, "longTerm": null, "equityHoldings": null, "totalAssets": 22126000, "ladder": null, "currentRatio": 1.41, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }